Wolverine Asset Management Upped Its Valeant Pharmaceuticals Intl (Put) (VRX) Position, Palatin Technologies Has 1.38 Sentiment

July 17, 2017 - By Marie Mckinney

Wolverine Asset Management Llc increased Valeant Pharmaceuticals Intl (Put) (VRX) stake by 1085.07% reported in 2016Q4 SEC filing. Wolverine Asset Management Llc acquired 218,100 shares as Valeant Pharmaceuticals Intl (Put) (VRX)’s stock declined 15.71%. The Wolverine Asset Management Llc holds 238,200 shares with $3.46 million value, up from 20,100 last quarter. Valeant Pharmaceuticals Intl (Put) now has $5.92 billion valuation. The stock rose 0.64% or $0.11 reaching $17.35 per share. About 13.28M shares traded. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since July 17, 2016 and is downtrending. It has underperformed by 65.21% the S&P500.

Palatin Technologies, Inc. is a biopharmaceutical company. The company has market cap of $68.12 million. The Firm is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. It currently has negative earnings. The Company’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Analysts await Palatin Technologies, Inc. (NYSEMKT:PTN) to report earnings on September, 19. They expect $-0.04 EPS, up 55.56% or $0.05 from last year’s $-0.09 per share. After $-0.02 actual EPS reported by Palatin Technologies, Inc. for the previous quarter, Wall Street now forecasts 100.00% negative EPS growth.

About 617,212 shares traded. Palatin Technologies, Inc. (PTN) has declined 19.98% since July 17, 2016 and is downtrending. It has underperformed by 36.68% the S&P500.

Sphera Funds Management Ltd. holds 0.37% of its portfolio in Palatin Technologies, Inc. for 2.91 million shares. Broadfin Capital Llc owns 3.85 million shares or 0.22% of their US portfolio. Moreover, Qvt Financial Lp has 0.07% invested in the company for 6.36 million shares. The New Jersey-based Sabby Management Llc has invested 0.05% in the stock. Alyeska Investment Group L.P., a Illinois-based fund reported 3.47 million shares.

Investors sentiment decreased to 0.78 in 2016 Q4. Its down 0.10, from 0.88 in 2016Q3. It fall, as 82 investors sold VRX shares while 87 reduced holdings. 49 funds opened positions while 82 raised stakes. 193.03 million shares or 13.22% less from 222.43 million shares in 2016Q3 were reported. Sei Investments holds 20 shares or 0% of its portfolio. Bnp Paribas Arbitrage holds 0.07% or 1.04M shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0.02% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) or 110,574 shares. Flow Traders Us Limited Liability Com holds 0.02% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 18,949 shares. First Manhattan reported 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Susquehanna Interest Llp owns 5.74 million shares or 0.04% of their US portfolio. Guggenheim Cap Ltd has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Acadian Asset Management Ltd Llc holds 69,500 shares or 0% of its portfolio. Silver Point LP invested in 0.89% or 570,000 shares. Riggs Asset Managment accumulated 0.03% or 4,193 shares. Cibc Asset Management Inc holds 484,618 shares or 0.05% of its portfolio. Royal Bancorporation Of Canada owns 2.83M shares or 0.02% of their US portfolio. Parallax Volatility Advisers LP reported 199,427 shares. Intact Investment Mngmt Inc stated it has 163,600 shares. Cohen Klingenstein Limited Liability reported 16,738 shares.

Among 25 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 3 Sell and 16 Hold. Therefore 24% are positive. Valeant Pharmaceuticals Intl had 107 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Friday, October 2. The firm has “Sector Perform” rating given on Tuesday, October 20 by IBC. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Monday, December 14 with “Outperform” rating. The stock has “Sector Perform” rating by IBC on Monday, November 30. The firm has “Neutral” rating given on Thursday, April 20 by JP Morgan. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, November 11. The firm has “Overweight” rating by JP Morgan given on Wednesday, March 16. BTIG Research maintained the stock with “Neutral” rating in Thursday, May 11 report. As per Friday, November 6, the company rating was maintained by Guggenheim. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Sector Outperform” rating given on Tuesday, October 20 by Scotia Capital.

Wolverine Asset Management Llc decreased Direxion Shs Etf Tr (Call) (SPXL) stake by 55,000 shares to 206,300 valued at $22.23 million in 2016Q4. It also reduced Amgen Inc (Put) (NASDAQ:AMGN) stake by 3,400 shares and now owns 700 shares. Carriage Svcs Inc (Put) (NYSE:CSV) was reduced too.

Since March 13, 2017, it had 3 insider purchases, and 1 insider sale for $166.26 million activity. Another trade for 24,000 shares valued at $257,280 was made by Herendeen Paul on Tuesday, March 14. Shares for $32.47 million were bought by ValueAct Holdings – L.P.. The insider Pershing Square Capital Management – L.P. sold 18.11 million shares worth $199.26 million. DE SCHUTTER RICHARD U also bought $278,000 worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Thursday, May 11.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.